Variceal hemorrhage in cirrhosis.

Area of Science:

• Gastroenterology
• Hepatology
• Clinical Medicine

Background:

• Variceal bleeding (VB) is a critical complication of cirrhosis, significantly impacting patient morbidity and mortality.
• The presence of other decompensating events in cirrhosis influences the management and prognosis of variceal bleeding.

Purpose of the Study:

• To review risk-stratified management and prevention strategies for variceal bleeding (VB) in cirrhosis.
• To outline acute therapy, indications for transjugular intrahepatic portosystemic shunt (TIPS), and primary/secondary prophylaxis for VB.

Main Methods:

• Literature search of PubMed/MEDLINE, prioritizing trials, meta-analyses, and clinical guidelines.
• Synthesis of expert opinion on current management practices for VB.
• Review of risk stratification criteria for decompensation and VB prevention.

Main Results:

• Standard acute VB management includes vasoconstrictors, antibiotics, and endoscopic variceal ligation (EVL).
• Pre-emptive TIPS placement offers survival benefits for high-risk patients (Child-Pugh 10-13 or 8-9 with active bleeding).
• Secondary prophylaxis involves nonselective beta-blockers (NSBBs) plus EVL; primary prophylaxis for high-risk varices uses NSBBs or EVL; NSBBs (preferably carvedilol) are recommended for compensated cirrhosis at high risk of decompensation.

Conclusions:

• Risk-stratified management is crucial for optimizing outcomes in patients with variceal bleeding.
• Early consideration of TIPS in high-risk patients and tailored prophylactic strategies are key to preventing VB and decompensation in cirrhosis.